CU20210008A7 - Aspirasas solubilizadas - Google Patents

Aspirasas solubilizadas

Info

Publication number
CU20210008A7
CU20210008A7 CU2021000008A CU20210008A CU20210008A7 CU 20210008 A7 CU20210008 A7 CU 20210008A7 CU 2021000008 A CU2021000008 A CU 2021000008A CU 20210008 A CU20210008 A CU 20210008A CU 20210008 A7 CU20210008 A7 CU 20210008A7
Authority
CU
Cuba
Prior art keywords
solubilized
aspirases
design
prevent
pharmaceutical compositions
Prior art date
Application number
CU2021000008A
Other languages
English (en)
Inventor
Agostino Cirillo
Hilmar Ebersbach
Boerje Haraldsson
Thomas Huber
Guido Junge
Regina Link
Max Warncke
Chao Zou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20210008A7 publication Critical patent/CU20210008A7/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

<p>La invención se refiere al diseño y uso terapéutico de polipéptidos de apirasa solubilizados,<br /> composiciones farmacéuticas, usos terapéuticos y métodos útiles para prevenir y tratar el daño tisular.</p>
CU2021000008A 2018-07-18 2019-07-17 Aspirasas solubilizadas CU20210008A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18184269 2018-07-18
PCT/IB2019/056117 WO2020016804A1 (en) 2018-07-18 2019-07-17 Solubilized apyrases, methods and use

Publications (1)

Publication Number Publication Date
CU20210008A7 true CU20210008A7 (es) 2021-08-06

Family

ID=62985993

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2021000008A CU20210008A7 (es) 2018-07-18 2019-07-17 Aspirasas solubilizadas

Country Status (26)

Country Link
US (1) US20220356455A1 (es)
EP (1) EP3824079A1 (es)
JP (2) JP7425784B2 (es)
KR (1) KR20210035806A (es)
CN (1) CN112424346A (es)
AR (1) AR115790A1 (es)
AU (1) AU2019306821B2 (es)
BR (1) BR112021000586A2 (es)
CA (1) CA3103684A1 (es)
CL (1) CL2021000129A1 (es)
CO (1) CO2021000210A2 (es)
CR (1) CR20210021A (es)
CU (1) CU20210008A7 (es)
EA (1) EA202190057A1 (es)
EC (1) ECSP21002804A (es)
IL (1) IL280191A (es)
JO (1) JOP20210008A1 (es)
MA (1) MA53177A (es)
MX (1) MX2021000542A (es)
PE (1) PE20210185A1 (es)
PH (1) PH12021550122A1 (es)
SG (1) SG11202011776RA (es)
TW (1) TW202016299A (es)
UY (1) UY38299A (es)
WO (1) WO2020016804A1 (es)
ZA (1) ZA202007187B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021243173A1 (en) * 2020-05-28 2021-12-02 Charm Sciences, Inc. Methods and assemblies for sample analysis
WO2024023746A1 (en) 2022-07-29 2024-02-01 Novartis Ag Improved production of cd39 variants
TW202404627A (zh) 2022-07-29 2024-02-01 瑞士商諾華公司 使用cd39、重組cd39用於急性器官損傷的治療

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6425699A (en) 1998-10-16 2000-05-08 Cornell Research Foundation Inc. Methods of inhibiting platelet activation and recruitment
US20020002277A1 (en) * 1998-10-16 2002-01-03 Maliszewski Charles Richard Inhibitors of platelet activation and recruitment
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
WO2006096989A2 (en) 2005-03-17 2006-09-21 National Research Council Of Canada Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression
WO2011088231A1 (en) * 2010-01-13 2011-07-21 Apt Therapeutics, Inc. Apyrase therapy for bleeding conditions
DK3083677T3 (da) 2013-12-20 2019-11-25 Novartis Ag Hidtil ukendte eukaryote celler og fremgangsmåder til rekombinant ekspression af et produkt af interesse
RU2720525C2 (ru) 2013-12-20 2020-04-30 Новартис Аг Новые эукариотические клетки и способы их получения для рекомбинантной экспрессии представляющего интерес продукта

Also Published As

Publication number Publication date
CA3103684A1 (en) 2020-01-23
AU2019306821A1 (en) 2020-12-24
CO2021000210A2 (es) 2021-01-18
JP2024023297A (ja) 2024-02-21
BR112021000586A2 (pt) 2021-04-06
KR20210035806A (ko) 2021-04-01
AR115790A1 (es) 2021-02-24
JP7425784B2 (ja) 2024-01-31
US20220356455A1 (en) 2022-11-10
PE20210185A1 (es) 2021-02-02
EP3824079A1 (en) 2021-05-26
SG11202011776RA (en) 2021-02-25
WO2020016804A1 (en) 2020-01-23
CR20210021A (es) 2021-03-23
CL2021000129A1 (es) 2021-08-20
MA53177A (fr) 2021-05-26
ZA202007187B (en) 2022-06-29
PH12021550122A1 (en) 2021-09-27
CN112424346A (zh) 2021-02-26
JOP20210008A1 (ar) 2021-01-12
JP2021529550A (ja) 2021-11-04
MX2021000542A (es) 2021-03-29
ECSP21002804A (es) 2021-04-29
TW202016299A (zh) 2020-05-01
UY38299A (es) 2020-02-28
AU2019306821B2 (en) 2022-09-29
EA202190057A1 (ru) 2021-08-24
IL280191A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2020003257A1 (es) Compuestos antagonistas de pcsk9.
PE20200494A1 (es) Polinucleotidos de aadc para el tratamiento de la enfermedad de parkinson
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
NI201000044A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2011003160A1 (es) Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras.
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
NI201000015A (es) Bromhidrato de bupropión y aplicaciones terapéuticas
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CO2018008450A2 (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
BR112015013675A2 (pt) composições compreendendo vortioxetina e donepezil
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino